SOX18在前列腺癌中的表达及与患者远期预后的关系

SOX18 Expression with Patients Long-term Prognosis in Prostate Cancer

【目的】探讨性别决定区Y框蛋白18(SOX18)在前列腺癌中的表达及与患者远期预后的关系。【方法】选择2013年1月至2018年3月本院收治的140例前列腺癌患者(观察组)的临床资料,同时选取良性前列腺增生组织112例作为对照组,采用免疫组化染色法检测SOX18表达,随访患者预后情况。【结果】观察组SOX18阳性表达率为70.00%(98/140),显著高子对照组的40.18%(45/112),差异有统计学意义(X2=22.545,P<0.05)。SOX18阳性患者中位总生存时间为50个月(95%CJ:43.81〜56.19),明显短于SOX18阴性患者的70个月[95%CJ(66.92〜73.08)],差异有统计学意义(X2=19.649,PC0.05)。将SOX18阳性表达、年龄、高血压、糖尿病、TNM分期等临床病理指标作为自变量,预后生存情况等作为因变量进行COX回归分析,结果显示TNM分期、Gleason评分、SOX18表达是前列腺癌患者预后的影响因素(只尺=2.748、2.392、1.426,P<0.05)。【结论】前列腺癌患者SOX18阳性表达率高,与临床分期、病理分级、PSA及Gleason有一定关系,同时对患者预后有一定影响。

【Objective】To investigate the expression of sex-determining region Y-box protein 18(SOX18)in prostate cancer and its relationship with long-term prognosis.【Methods】A total of 140 patients with prostate cancer treated in our hospital from January 2012 to March 2017 were selected as the prostate cancer group,and 112 patients with benign prostatic hyperplasia were selected as the control group.The expression of SOXl 8 was detected by immu-nohistochemical staining,and the prognosis of patients was followed up.【Results】The positive expression rate of SOX18 in prostate cancer group was 70.00%(98/140),which was significantly higher than that in control group 40.18%(45/112).The difference was statistically significant(P<0.05).The positive expression rates of SOXl8 in patients with TNM stage IE-IV»pathological grade G3-G4,PSA level〉20 ng/mL and Gleason score≥8 were 88.24½*83.05%,88.89%and 80.49%,respectively,which were significantly higher than those in patients with stage I-[I'Gi-G2»prostate specific antigen(PSA)≤20 ng/mL and Gleason score(P<0.05).The median o verall survival time of SOXl8 positive patients was 50 months,which was significantly shorter than that of SOXl8 negative patients(70 months);the difference was statistically significant(P<0.05).COX regression analysis showed that TNM stage,Gleason score and SOXl8 expression were the prognostic factors of prostate cancer patients(HR=2.748,2.392 and 1.426,P<0.05).【Conclusion】The expression of SOX18 in prostate cancer is significantly up-regulated,which are related to clinical stage»pathological grade,PSA and Gleason,and also affect the prognosis of patients.